Maintenance prophylactic treatment of asthma in patients 5 yr of age and older; asthma patients requiring systemic corticosteroid administration in which adding an inhaled corticosteroid may reduce or eliminate need for systemic corticosteroids.
Adults and children 12 yr of age and older:PO Oral inhalation If previous therapy consisted of bronchodilators alone, start with 40 or 80 mcg twice daily (max dose, 320 mcg twice daily); if previous therapy consisted of inhaled corticosteroids, start with 40 to 160 mcg twice daily (max dose, 320 mcg twice daily).
Children 5 to 11 yr of age:PO Oral inhalation If previous therapy consisted of bronchodilators alone or inhaled corticosteroids, start with 40 mcg twice daily (max dose, 80 mcg twice daily).
Nasopharyngeal irritation (24%); sneezing attacks (4%); nasal stuffiness, nosebleeds, rhinorrhea, tearing eyes (less than 3%); dryness, irritation of the nose and throat, unpleasant taste and smell. GI:
Nausea (at least 3%).
Nausea (less than 5%). GU:
Dysmenorrhea (1% to 3%). METAB: Suppression of hypothalamic-pituitary-adrenal (HPA) function. RESP:
Increased asthma symptoms, upper respiratory tract infections (at least 3%); coughing (1% to 3%). OTHER: Growth velocity reduction in children; rare cases of immediate and delayed hypersensitivity reaction with angioedema, bronchospasm, rash, and urticaria; weight gain.
Back pain, dysphonia, oral symptoms, pain (at least 3%).
Absorption: 20%. Action is primarily local following inhalation.
Distribution: Crosses the placenta and enters breast milk in small amounts.
Metabolism/Excretion: Following inhalation, beclomethasone dipropionate is primarily converted to beclomethasone 17–monopropionate (active metabolite); primarily excreted in feces (<10% excreted in urine).